Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669482 · ClinicalTrials.gov registry record · Phase 1
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
A Phase 1 study of Metastatic Cancer and Pancreas Cancer, sponsored by Verastem.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 12
- Study locations
NCT05669482: Active Phase 1 study of Metastatic Cancer and Pancreas Cancer, sponsored by Verastem.
NCT05669482 is a Phase 1 study of Metastatic Cancer and Pancreas Cancer that is active but no longer recruiting, run by Verastem. The registered enrollment target is 40 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669482, a Phase 1 study of Metastatic Cancer and Pancreas Cancer, is active but no longer recruiting, sponsored by Verastem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Primary Outcome
Assessment of Dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
Study Locations (12)
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- New York Presbyterian/Weill-Cornell Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- Virginia Mason Medical Center - Seattle
- Fred Hutchinson Cancer Center - Seattle
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Cancer Center - Ann Arbor
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-03-22 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
What the registry record for NCT05669482 still lists
NCT05669482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel is the first listed.
NCT05669482 lists 12 locations in 9 states (New York, Washington, California).
Frequently Asked Questions
What is clinical trial NCT05669482 about?
NCT05669482 is a clinical study titled "Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer". This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
What is the current status of trial NCT05669482?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-03-22. Estimated completion is 2027-08-31.
What conditions does trial NCT05669482 study?
This clinical trial studies the following conditions: Metastatic Cancer, Pancreas Cancer, KRAS Activating Mutation, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas.
What interventions are being tested in trial NCT05669482?
The interventions under investigation include: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT05669482?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669482 being conducted?
This trial has 12 study locations across California, Illinois, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05669482's enrollment target sits among peer trials
40 67th of 109 higher than 38 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI